Search

Displaying results 3411 - 3420 of 10000 in total
  1. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

  2. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients. … Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile.

  3. Drug

    Parnaparin

    go.drugbank.com/drugs/DB09260
    Approved

    Parnaparin is an heparin of low molecular weight with antithrombotic effects.

  4. Drug

    Levallorphan

    go.drugbank.com/drugs/DB00504
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p683) … An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties.

  5. Drug

    Azadirachtin

    go.drugbank.com/drugs/DB19419
    Investigational

    Azadirachtin is under investigation in clinical trial NCT06617026 (Short-term Outcome of Medical vs. Surgical Management of Chronic Anal Fissure).

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Octamoxin

    go.drugbank.com/drugs/DB09249
    ApprovedWithdrawn

    This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

  7. Drug

    Phenprocoumon

    go.drugbank.com/drugs/DB00946
    ApprovedInvestigationalWithdrawn

    Coumarin derivative that acts as a long-acting oral anticoagulant.

  8. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    The other is an antibody that targets tumours. It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.

  9. Drug

    Basiliximab

    go.drugbank.com/drugs/DB00074
    ApprovedInvestigational

    known as CD25 antigen) on the surface of activated T-lymphocytes. … A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also

  10. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.